Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

This will play a video. - A man in a pool is wearing purple goggles.

TRANSCATHETER AORTIC HEART VALVE IMPLANTATION (TAVI)

Our Evolut™ platform lets you go above and beyond in managing patients with symptomatic severe aortic stenosis.

A MINIMALLY INVASIVE OPTION FOR THE TREATMENT OF SEVERE AORTIC STENOSIS

TAVI is a minimally invasive, catheter-based procedure to replace the function of the aortic valve. Indicated for patients at intermediate or greater risk for open heart surgery, TAVI may be an excellent option for certain patients because the prevalence of aortic stenosis and co-morbidities may increase the risks associated with surgical aortic valve replacement (SAVR).

The Evolut™ TAVI System is the only TAVI platform on the market that demonstrates significantly better outcomes in all-cause mortality or stroke over surgery in high-risk patients at 3 years.1

LEADING HEMODYNAMICS

Designed for large EOAs, low gradients, and minimal patient prosthesis mismatch, the Evolut TAV allows your patient to return to activity faster.*

SEE THE DATA

REAL-World RESULTS

Five-year results demontstrated meaningful treatment for patients with sever symptomatic aortic stenosis^.†

SEE THE DATA

Popma JJ. SURTAVI: Two Year Complete Results from a Randomized Trial of a Self-expanding Transcatheter Heart Valve vs. Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk. Presented at TCT 2018; San Diego, CA.

^†

Deeb, et. al, J Am Coll Cardiol. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Implantation, 2016 Jun 7;67(22):2565-74.